Latest research on Salmeterol

Salmeterol is a long-acting beta2-adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.

Latest findings

The Prevention Of Exacerbations with Tiotropium in COPD (POET) study showed that long-acting bronchodilator therapy with the anti-cholinergic drug tiotropium was superior to a LABA, Salmeterol, in preventing exacerbations in patients with moderate to severe COPD at risk of exacerbation. [source, 2016]
Time to first exacerbation was increased (187 vs 145 days; hazard ratio 0.83; P<0.001), and the annual number of moderate or severe exacerbations was reduced (0.64 vs 0.72; P=0.02) with tiotropium compared with Salmeterol. [source, 2016]
Interestingly, the response to Salmeterol can be influenced by the β2-adrenergic receptor genotype. [source, 2016]
Patients with the Arg16Arg genotype had a reduced risk of exacerbation in response to Salmeterol than those with the Arg16Gly and Gly16Gly genotypes.55 [source, 2016]
The annual incidence of moderate or severe exacerbations, systemic corticosteroid prescriptions, and hospitalizations were reduced significantly in the TORCH study with both the β2-agonist Salmeterol and corticosteroid Fluticasone. [source, 2016]
Roflumilast added on to a regimen of tiotropium and Salmeterol resulted in an incremental cost-effectiveness ratio of £13,764/quality-adjusted life-year gained. [source, 2016]
Among adult patients with asthma inadequately controlled on low-dose ICS, tiotropium 18-mcg add-on was superior to double ICS dose and noninferior to Salmeterol 50-mcg bid add-on in improving morning peak expiratory flow [50]. [source, 2016]
Now several different types of inhaled beta-2 adrenergic agonists are available in clinical practice; short-acting beta-2 agonists (SABA) like Salbutamol, LABA like Salmeterol or formoterol, and ultra-LABA like indacaterol. [source, 2016]
In previous clinical trial comparing Salmeterol with placebo added to usual therapy, Salmeterol group had a higher rate of asthma-related deaths (odds ratio, 4.37) [33]. [source, 2016]
In recent Cochrane group meta-analyses of randomized controlled trials (RCTs) comparing regular ICS+LABA (either Salmeterol or formoterol) vs. same-dose ICS groups, no significant differences were found in fatal or nonfatal serious adverse events between two groups [3435]. [source, 2016]